Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Posters, Sunday and Monday<br />
Index of Poster Presenters cont’d<br />
07P12<br />
Pharmacok<strong>in</strong>etic, Efficacy and Safety Data of the First<br />
Recomb<strong>in</strong>ant Factor VIII from a Human Cell L<strong>in</strong>e<br />
Knaub S1 , Jansen M1 , Zozulya N2 , Plyushch O2 1 2 Octapharma AG, Hematology Scientific Center of Russian<br />
Academy of Medical Science, Lachen, Russia<br />
07P13<br />
A Prospective, Randomized, and Crossover Study of an<br />
Activated Prothromb<strong>in</strong> Complex Concentrate for Secondary<br />
Prophylaxis <strong>in</strong> Patients with Hemophilia A and Inhibitors (Pro-<br />
FEIBA): Subject Demographics and Safety Data<br />
Leiss<strong>in</strong>ger C1 , Négrier C2 , Berntorp E3 , W<strong>in</strong>dyga J4 , Serban<br />
M5 , Bülent A6 , Lassila R7 , Kavakli K8 , Zulfikar B9 , Gr<strong>in</strong>geri A10 1Louisiana Center For Bleed<strong>in</strong>g And Clott<strong>in</strong>g, Tulane<br />
University Medical Center, Tulane, France 2Hemophilia Treatment Center, Hôpital Edouard Herriot, University Claude<br />
Bernard, Lyon, France, 3Malmö University Hospital, Malmö<br />
Centre for Thrombosis and Hemostasis, Malmö, Sweden,<br />
4Institute of Hematology and Transfusion Medic<strong>in</strong>e, Warsaw,<br />
Poland, 5Emergency Cl<strong>in</strong>ic for Children, Timisoara, Romania,<br />
6 7 Çukurova University, Adana, Turkey, Division of Coagulation<br />
Disorders, Hels<strong>in</strong>ki University Central Hospital, Hels<strong>in</strong>ki,<br />
F<strong>in</strong>land, 8University of Ege, Izmir, Turkey, 9Istanbul University,<br />
10 Istanbul, Turkey, Bianchi Bonomi Hemophilia and<br />
Thrombosis Center, University of Milan, Milan, Italy<br />
07P14<br />
Phase I, Randomized, Double-Bl<strong>in</strong>d, Placebo-Controlled,<br />
S<strong>in</strong>gle-Dose Escalation Study of the rFVIIa Variant (BAY 86-<br />
6150) <strong>in</strong> Hemophilia A or B with or without Inhibitors<br />
Mahlangu J1 , Coetzee M2 , Laffan M3 , W<strong>in</strong>dyga J4 , Yee T5 ,<br />
Schroeder J6 1Hemophilia Comprehensive Care Center, Charlotte Maxeke<br />
Johannesburg Academic Hospital And University Of The<br />
Witwatersrand, 2Bloemfonte<strong>in</strong> Haemophilia Treatment<br />
Centre, University of the Free State, Bloemfonte<strong>in</strong>, South<br />
Africa, 3Imperial College, Hammersmith Hospital, London,<br />
U.K., 4Institute of Hematology and Transfusion Medic<strong>in</strong>e,<br />
Warsaw, Poland, 5The Royal Free Hospital, London, U.K.,<br />
6Bayer Scher<strong>in</strong>g Pharma AG, Berl<strong>in</strong>, Germany<br />
07P15<br />
Long-Term Cl<strong>in</strong>ical Safety of FEIBA, Activated Prothromb<strong>in</strong><br />
Complex Concentrate (APCC) <strong>in</strong> Japanese Inhibitor Subjects:<br />
An Update of Post-Authorization Safety Surveillance (PASS)<br />
<strong>Program</strong><br />
Midori S 1 , Kagehiro A2 , Ei K3 , Sh<strong>in</strong>ji M4 , Tadashi M5 , Satoshi<br />
H6 , Teruhisa F7 , Michio S8 and the FINE study group9 1 2 Nara Medical University, Nara Tokyo Medical University<br />
Hospital, 3Ogikubo Hospital, 4St. Marianna University School<br />
of Medic<strong>in</strong>e, Kanagawa, 5Nagoya University School of<br />
Medic<strong>in</strong>e, Aichi, 6Hyogo College of Medic<strong>in</strong>e, Hyogo,<br />
7 8 Hiroshima University Hospital, Hiroshima, University of<br />
Environmental and Occupational Health Japan, Fukuoka,<br />
and 9Baxter BioScience Japan, Medical Affairs Cl<strong>in</strong>ical Trial,<br />
Tokyo, Japan<br />
50<br />
07P16<br />
Long-Act<strong>in</strong>g Glycopegylated Recomb<strong>in</strong>ant Activated Factor<br />
VII (LA-rFVIIa) is Safe and Shows a Prolonged FVIIa Half-Life<br />
after S<strong>in</strong>gle and Multiple Adm<strong>in</strong>istrations <strong>in</strong> Hemophilia A<br />
and B Patients, Mak<strong>in</strong>g it Suitable for Development as<br />
Prophylactic Treatment of Patients with Hemophilia and<br />
Inhibitors<br />
Møss J1 , Stenmo C1 , Jimenez-Yuste V2 , Bottcher S1 ,<br />
Fernandez, I2 1 2 Novo Nordisk A/S, Denmark, Hospital Universitario La Paz,<br />
Madrid, Spa<strong>in</strong><br />
07P17<br />
Efficacy, Safety and Immunogenicity of Wilate ® <strong>in</strong> Children<br />
Under 6 Years of Age with Inherited von Willebrand Disease<br />
Nowak-Goettl U1 , Kruempel A1 , Russo A2 , Jansen M3 , Knaub S4 1University Hospital, Westfälische Wilhelms-Universität,<br />
Münster, Germany, 2University Hospital, Johannes Gutenberg-<br />
3 Universität Ma<strong>in</strong>z, Germany, Octapharma Produk -<br />
tionsgesellschaft mbH, Vienna, Austria, 4Octapharma AG,<br />
Lachen, Switzerland<br />
07P18<br />
Safety and Efficacy of B-Doma<strong>in</strong>-Deleted Recomb<strong>in</strong>ant FVIII<br />
– <strong>F<strong>in</strong>al</strong> Results of a 10-Year Pharmacovigiliance Study<br />
Westfeld M1 , Pollmann H2 for the ReFacto ® Phar -<br />
macovigilance Data Monitor<strong>in</strong>g Board<br />
1Wyeth Pharma GmbH - e<strong>in</strong> Unternehmen der Pfizer-Gruppe,<br />
2 Muenster, ITH - Institut für Thrombophilie und<br />
Haemostaseologie, Bonn, Germany<br />
07P19<br />
Two-year Interim Results of a Non-Interventional Trial to<br />
Assess the Safety and Efficacy of Treatment with<br />
Recomb<strong>in</strong>ant Factor IX<br />
Westfeld M1 , Pollmann H2 , Oldenburg J3 1Wyeth Pharma GmbH - e<strong>in</strong> Unternehmen der Pfizer-Gruppe,<br />
2 Muenster, ITH - Institut für Thrombophilie und<br />
Haemostaseologie, 3Universitaetskl<strong>in</strong>ikum Bonn, Germany<br />
07P20<br />
Cl<strong>in</strong>ical Efficacy of a Novel VWF-Conta<strong>in</strong><strong>in</strong>g FVIII<br />
Concentrate, Wilate ® , <strong>in</strong> the Prophylaxis and Treatment of<br />
Bleed<strong>in</strong>g Episodes <strong>in</strong> Previously Treated Hemophilia A<br />
Patients<br />
Klukowska A1 , W<strong>in</strong>dyga J2 , Batorova A3 1Department of Pediatrics, Hematology and Oncology,<br />
Medical University of Warsaw, Warszawa, Poland,<br />
2Department of Hemostasis Disturbances and Internal<br />
Diseases, Institute of Hematology and Transfusiology,<br />
Warszawa, Poland, 3University Hospital Cl<strong>in</strong>ic Haematology<br />
& Blood Transfusion, Bratislava, Slovak Republic